504594 Gemcitabine, HCl - CAS 122111-03-9 - Calbiochem

504594
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service
      Voir les Prix & la Disponibilité

      Aperçu

      Replacement Information

      Tableau de caractéristiques principal

      Empirical FormulaCAS #
      C₉H₁₁F₂N₃O₄ • HCl 122111-03-9

      Prix & Disponibilité

      Référence DisponibilitéConditionnement Qté Prix Quantité
      5045940001
      Récupération des données relatives à la disponibilité...
      Disponibilité limitéeDisponibilité limitée
      En stock 
      Interrompu(e)
      Disponible en quantités limitées
      Disponibilité à confirmer
        Pour le restant : Nous vous tiendrons informé
          Pour le restant : Nous vous tiendrons informé
          Nous vous tiendrons informé
          Contacter le Service Clients
          Contact Customer Service

          Flacon en verre 50 mg
          Prix en cours de récupération
          Le prix n'a pas pu être récupéré
          La quantité minimale doit être un multiple de
          À la validation de la commande Plus d'informations
          Vous avez sauvegardé ()
           
          Demander le prix
          Description
          OverviewA bioavailable, moderately toxic, deoxyctytidine analog with anti-metabolite and anti-tumor properties. Shown to be effective against a variety of tumors and blocks the growth of cancer cells in culture (IC 50 = 8.7, 57, 3.7, and 36 nM for L1210, CEM, Caco2, and HeLa cells, respectively). Following its uptake into cells by nucleoside transporters it is phosphorylated to its mono (dFdCMP), di (dFdCDP), and triphosphorylated (dFdCTP) forms by deoxycytidine kinase. dFdCDP and dFdCTP are reported to inhibit the activity of ribonucleotide reductase and impede DNA synthesis and repair mechanisms and induce cell death. Blocks the progression of cells through the G1/S phase. The dFdCTP is shown to compete with endogenous deoxycytidine triphosphate (dCTP) for incorporation into DNA and against CTP into RNA. Gemcitabine is also shown to block mitochondrial DNA polymerase γ. Works synergistically with other chemotherapeutic agents to enhance their cytotoxicity. Its half life is reported to be 42 to 94 min (depending upon the age and sex of the individual).
          Catalogue Number504594
          Brand Family Calbiochem®
          SynonymsLY188011, dFdC, dFdCyd, 2ʹ,2ʹ-Difluoro-2ʹ-deoxycytidine, HCl, 2ʹ-Deoxy-2ʹ,2ʹ-difluorocytidine, HCl, 4-Amino-1-((2R,5S)-3,3-difluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one, HCl, Ribonucleotide Reductase Inhibitor II, RNR Inhibitor II
          References
          ReferencesHung, S.W., et al. 2012. Cancer Lett. 320, 138.
          Fowler, J.D., et al. 2008. J. Biol. Chem. 283, 15339.
          Mackey, J.R., et al. 1998. Cancer Res. 58, 4349.
          Eda, H., et al. 1998. Cancer Res. 58, 1165.
          Burris III, H.A., et al. 1997. J. Clin. Oncol. 15, 2403.
          Heinemann, V., et al. 1992. Cancer Res. 52, 533.
          Hertel, L.W., et al. 1990. Cancer Res. 50, 4417.
          Product Information
          CAS number122111-03-9
          FormWhite powder
          Hill FormulaC₉H₁₁F₂N₃O₄ • HCl
          Chemical formulaC₉H₁₁F₂N₃O₄ • HCl
          Hygroscopic Hygroscopic
          ReversibleN
          Quality LevelMQ100
          Applications
          Biological Information
          Primary TargetDNA
          Secondary targetDNA polymerase
          Purity≥99% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          R PhraseR: 62-63

          Possible risk of impaired fertility.
          Possible risk of harm to the unborn child.
          S PhraseS: 36/37-53

          Wear suitable protective clothing and gloves.
          Avoid exposure - obtain special instructions before use.
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Carcinogenic / Teratogenic
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Gemcitabine, HCl - CAS 122111-03-9 - Calbiochem FDS

          Titre

          Fiche de données de sécurité des matériaux (FDS) 

          Gemcitabine, HCl - CAS 122111-03-9 - Calbiochem Certificats d'analyse

          TitreNuméro de lot
          504594

          Références bibliographiques

          Aperçu de la référence bibliographique
          Hung, S.W., et al. 2012. Cancer Lett. 320, 138.
          Fowler, J.D., et al. 2008. J. Biol. Chem. 283, 15339.
          Mackey, J.R., et al. 1998. Cancer Res. 58, 4349.
          Eda, H., et al. 1998. Cancer Res. 58, 1165.
          Burris III, H.A., et al. 1997. J. Clin. Oncol. 15, 2403.
          Heinemann, V., et al. 1992. Cancer Res. 52, 533.
          Hertel, L.W., et al. 1990. Cancer Res. 50, 4417.
          Fiche technique

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision01-July-2013 JSW
          SynonymsLY188011, dFdC, dFdCyd, 2ʹ,2ʹ-Difluoro-2ʹ-deoxycytidine, HCl, 2ʹ-Deoxy-2ʹ,2ʹ-difluorocytidine, HCl, 4-Amino-1-((2R,5S)-3,3-difluoro-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one, HCl, Ribonucleotide Reductase Inhibitor II, RNR Inhibitor II
          DescriptionA bioavailable, moderately toxic, deoxyctytidine analog with anti-metabolite and anti-tumor properties. Shown to be effective against a variety of tumors and blocks the growth of cancer cells in culture (IC 50 = 8.7, 57, 3.7, and 36 nM for L1210, CEM, Caco2, and HeLa cells, respectively). Following its uptake into cells by nucleoside transporters it is phosphorylated to its mono (dFdCMP), di (dFdCDP), and triphosphorylated (dFdCTP) forms by deoxycytidine kinase. dFdCDP and dFdCTP are reported to inhibit the activity of ribonucleotide reductase and impede DNA synthesis and repair mechanisms and induce cell death. Blocks the progression of cells through the G1/S phase. The dFdCTP is shown to compete with endogenous deoxycytidine triphosphate (dCTP) for incorporation into DNA and against CTP into RNA. Gemcitabine is also shown to block mitochondrial DNA polymerase γ. Works synergistically with other chemotherapeutic agents to enhance their cytotoxicity. Its half life is reported to be 42 to 94 min (depending upon the age and sex of the individual).
          FormWhite powder
          Intert gas (Yes/No) Packaged under inert gas
          CAS number122111-03-9
          Chemical formulaC₉H₁₁F₂N₃O₄ • HCl
          Purity≥99% by HPLC
          SolubilityH₂O (25 mg/ml)
          Storage +2°C to +8°C
          Hygroscopic
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Carcinogenic / Teratogenic
          ReferencesHung, S.W., et al. 2012. Cancer Lett. 320, 138.
          Fowler, J.D., et al. 2008. J. Biol. Chem. 283, 15339.
          Mackey, J.R., et al. 1998. Cancer Res. 58, 4349.
          Eda, H., et al. 1998. Cancer Res. 58, 1165.
          Burris III, H.A., et al. 1997. J. Clin. Oncol. 15, 2403.
          Heinemann, V., et al. 1992. Cancer Res. 52, 533.
          Hertel, L.W., et al. 1990. Cancer Res. 50, 4417.